An Observational Study to Predict Neonatal Hypoglycemia Using Antenatal Continuous Glucose Monitoring Among Late Preterm Parturients Receiving Corticosteroids
An Observational Study to Predict Neonatal Hypoglycemia Using Antenatal Continuous Glucose Monitoring Among Late Preterm Parturients Receiving Corticosteroids
Women undergoing late preterm birth are at high risk of delivering a newborn with neonatal hypoglycemia. The investigators plan to monitor interstitial glucose levels prior to delivery in these women in order to develop a better understanding of the relationship between maternal hyperglycemia and neonatal hypoglycemia.
Inclusion Criteria:
Pregnancy admitted to labor and delivery between 34w0d and 36w5d
English speaking women
High probability of delivery in late preterm period defined by any of the following:
Received at least one dose of corticosteroid within twelve hours of enrollment
Exclusion Criteria:
Any prior antenatal corticosteroid course in current pregnancy
Systemic corticosteroid administration during current pregnancy
Fetal demise or known major fetal anomaly, including cardiac anomaly or hydrops
Maternal contraindication to betamethasone: hypersensitivity reaction to any component of the medication, idiopathic thrombocytopenic, purpura, systemic fungal infection, or current use of amphotericin B
Diabetes, pregestational or gestational
Preexisting plan for intrapartum monitoring of maternal glucose levels for any reason
Delivery expected within 12 hours of randomization, because of insufficient time for corticosteroids to confer benefit, including:
To ensure that there is an adequate proportion of women presenting at 34 to 35 weeks gestation, enrollment will be restricted so that no more than 50% of the women in the trial present at 36 weeks.